Relative Bioavailability of Sotorasib Following Administration as a Water Dispersion to Healthy Subjects and Compatibility With Enteral Administration

• Published in: Clinical pharmacology in drug development Vol. 14; no. 1; p. 44
• Main Authors: Cardona, Panli, Spring, Marintan, Bao, Jiemin, Xie, Yong, Houk, Brett
• Format: Journal Article
• Language: English
• Published: United States 01.01.2025
• Subjects: pharmacokinetics; enteral feeding; water dispersion; biopharmaceutics; sotorasib

Sotorasib is approved to be taken as 960 mg orally once daily (8 × 120-mg tablets) for the treatment of KRAS G12C-mutated nonsmall cell lung cancer. Dispersion of tablets in water could be an alternative method for patients who require a liquid formulation due to dysphagia and enteral administration...